Leidos Holdings, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$1.11B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LDOS stock price vs TECH: inconclusive — current versus $692.22 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TECH's multiple
Implied fair value · at LDOS's multiple
Needs LDOS P/E.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Leidos Holdings, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
BIO-TECHNE Corp · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
INTERNATIONAL BUSINESS MACHINES CORP
LDOS vs IBM
Accenture plc
LDOS vs ACN
LOCKHEED MARTIN CORP
LDOS vs LMT
NORTHROP GRUMMAN CORP /DE/
LDOS vs NOC
GENERAL DYNAMICS CORP
LDOS vs GD
ZEBRA TECHNOLOGIES CORP
LDOS vs ZBRA
THERMO FISHER SCIENTIFIC INC.
LDOS vs TMO
DANAHER CORP /DE/
LDOS vs DHR
AGILENT TECHNOLOGIES, INC.
LDOS vs A
WATERS CORP /DE/
LDOS vs WAT
ILLUMINA, INC.
LDOS vs ILMN
BRUKER CORP
LDOS vs BRKR
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe TECH-like multiples require LDOS to deliver much faster growth and a fundamentally different margin structure, then avoid underwriting TECH-implied price and instead anchor to LDOS’s historical band and DCF range because LDOS already screens as profitable and fairly valued rather than obvious upside at current levels.
LDOS trades at 10.6x P/E, 0.9x P/S, and 6.8x EV/EBITDA versus TECH at 156.9x, 9.3x, and 48.0x, respectively, so the valuation gap is extreme. However, the implied price of $1,748.01 is driven by applying TECH-like multiples to LDOS, which is hard to justify given LDOS’s slower revenue growth and much larger, lower-margin profile.
Supporting Metrics